Cantel Medical Corp. (NYSE:CMD) has received a consensus broker rating score of 2.25 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. Cantel Medical’s rating score has improved by 10% from three months ago as a result of a number of analysts’ ratings changes.
Brokerages have set a 1-year consensus price target of $120.00 for the company and are anticipating that the company will post $0.58 EPS for the current quarter, according to Zacks. Zacks has also assigned Cantel Medical an industry rank of 162 out of 265 based on the ratings given to its competitors.
Shares of Cantel Medical (CMD) traded up $0.21 during mid-day trading on Monday, hitting $116.03. The stock had a trading volume of 20,244 shares, compared to its average volume of 105,590. Cantel Medical has a twelve month low of $69.21 and a twelve month high of $116.79. The stock has a market capitalization of $4,841.95, a PE ratio of 64.28 and a beta of 1.25. The company has a current ratio of 2.44, a quick ratio of 1.48 and a debt-to-equity ratio of 0.31.
The company also recently declared a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Stockholders of record on Wednesday, January 17th will be given a $0.085 dividend. The ex-dividend date of this dividend is Tuesday, January 16th. This represents a dividend yield of 0.17%. This is a boost from Cantel Medical’s previous Semi-Annual dividend of $0.07. Cantel Medical’s dividend payout ratio (DPR) is currently 9.39%.
Several hedge funds have recently made changes to their positions in the company. Globeflex Capital L P purchased a new stake in shares of Cantel Medical during the 2nd quarter worth approximately $114,000. Hartford Investment Management Co. purchased a new stake in shares of Cantel Medical during the 3rd quarter worth approximately $217,000. World Asset Management Inc purchased a new stake in shares of Cantel Medical during the 3rd quarter worth approximately $224,000. Waldron LP bought a new position in Cantel Medical in the 3rd quarter worth approximately $232,000. Finally, Ingalls & Snyder LLC bought a new position in Cantel Medical in the 3rd quarter worth approximately $235,000. Institutional investors and hedge funds own 86.46% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Cantel Medical Corp. (CMD) to Post $0.58 EPS” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/29/analysts-anticipate-cantel-medical-corp-cmd-to-post-0-58-eps.html.
About Cantel Medical
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.